Author:
Pond Gregory R.,Sonpavde Guru,de Wit Ronald,Eisenberger Mario A.,Tannock Ian F.,Armstrong Andrew J.
Reference10 articles.
1. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis;Armstrong;Clin Cancer Res,2007
2. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival;Armstrong;Eur J Cancer,2010
3. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group;Scher;J Clin Oncol,2008
4. A prognostic model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel [abstract 5013];Chi;J Clin Oncol,2013
5. Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial [abstract 5065];Loriot;J Clin Oncol,2013
Cited by
142 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献